• W Robert Simons is a seasoned, hands-on market access specialist and econometrician with leadership skills and business acumen and well-documented ability to think strategically and execute.• Applied to Health Technology Assessments (HTA) globally, he successfully achieved broad public listings at favorable and sustainable prices for close to twenty drugs in Australia, Canada, Asia (i.e., South Korea and Taiwan), Latin and South America and across Europe.• He’s also built, trained and mentored multiple Health Economic and Outcomes Research (HEOR) teams in the U.S., U.K., Germany, Paris, Canada, Taiwan, South Korea, Brazil, Mexico and Australia. In the last few years, these teams submitted HTA dossiers for two drugs, one in metastatic breast cancer and one in epilepsy. Eleven of the twelve submissions were approved.• With business acumen, he built a successful global consultancy with an Australian subsidiary that was also a preferred analyst and service provider for the Australia Department of Health and Aging with an eighty percent approval rate.• Within industry as global Market Access/ HTA lead, he integrated health economics and outcomes research, and more specifically, regional Market Access needs into clinical development and regulatory strategies for registration submissions.• As a new initiative -seeking to have quality of life added to label- he worked with regulatory and clinical development and regulatory authorities (i.e., FDA, EMA and Australia TGA) for quality of life endpoints to be included in label.Built, inspired and motivated effective Outcomes Research and Regional HTA Teams in all but one continent.